drugset / Trial / NCT06164327
Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, open Phase Ib clinical study to evaluate the safety,efficacy and pharmacokinetics of BEBT-908 combined with Rituximab (R) or combined with Rituximab-Gemcitabine-Oxaliplatin (R-GemOx) or combined with Rituximab-Ifosfamide-Carboplatin-Etoposide (R-ICE) in the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL).
Timeline
- Start
- 2023-12-01
- Primary completion
- 2025-10-31
- Completion
- 2025-11-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BEBT-908 | Unknown | 15 mg/m2 | — |
| Subject | BEBT-908 | Unknown | 22.5 mg/m2 | — |
| Subject | Carboplatin | Small molecule | 800 mg | — |
| Subject | Etoposide | Small molecule | 100 mg/m2 | — |
| Subject | Gemcitabine | Small molecule | 1 g | — |
| Subject | Ifosfamide | Small molecule | 5000 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 100 mg/m2 | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |